389 related articles for article (PubMed ID: 29511130)
1. Desirable Low-Density Lipoprotein Cholesterol Levels for Preventing Stroke Recurrence: A Post Hoc Analysis of the J-STARS Study (Japan Statin Treatment Against Recurrent Stroke).
Hosomi N; Kitagawa K; Nagai Y; Nakagawa Y; Aoki S; Nezu T; Kagimura T; Maruyama H; Origasa H; Minematsu K; Uchiyama S; Matsumoto M;
Stroke; 2018 Apr; 49(4):865-871. PubMed ID: 29511130
[TBL] [Abstract][Full Text] [Related]
2. Different Influences of Statin Treatment in Preventing At-Risk Stroke Subtypes: A Post Hoc Analysis of J-STARS.
Hosomi N; Kitagawa K; Nagai Y; Nakagawa Y; Aoki S; Nezu T; Kagimura T; Maruyama H; Origasa H; Minematsu K; Uchiyama S; Matsumoto M;
J Atheroscler Thromb; 2020 May; 27(5):449-460. PubMed ID: 31534062
[TBL] [Abstract][Full Text] [Related]
3. Cumulative Effects of LDL Cholesterol and CRP Levels on Recurrent Stroke and TIA.
Kitagawa K; Hosomi N; Nagai Y; Kagimura T; Ohtsuki T; Maruyama H; Origasa H; Minematsu K; Uchiyama S; Nakamura M; Matsumoto M;
J Atheroscler Thromb; 2019 May; 26(5):432-441. PubMed ID: 30318492
[TBL] [Abstract][Full Text] [Related]
4. Pravastatin Reduces the Risk of Atherothrombotic Stroke when Administered within Six Months of an Initial Stroke Event.
Hosomi N; Nagai Y; Kitagawa K; Nakagawa Y; Aoki S; Nezu T; Kagimura T; Maruyama H; Origasa H; Minematsu K; Uchiyama S; Matsumoto M;
J Atheroscler Thromb; 2018 Mar; 25(3):262-268. PubMed ID: 28924103
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: analysis of data from the MEGA Study, a large randomized controlled trial.
Uchiyama S; Nakaya N; Mizuno K; Ohashi Y; Tajima N; Kushiro T; Teramoto T; Nakamura H;
J Neurol Sci; 2009 Sep; 284(1-2):72-6. PubMed ID: 19423132
[TBL] [Abstract][Full Text] [Related]
6. Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack.
Byun YS; Yang X; Bao W; DeMicco D; Laskey R; Witztum JL; Tsimikas S;
J Am Coll Cardiol; 2017 Jan; 69(2):147-158. PubMed ID: 28081824
[TBL] [Abstract][Full Text] [Related]
7. Rationale, design, and baseline features of a randomized controlled trial to assess the effects of statin for the secondary prevention of stroke: the Japan Statin Treatment Against Recurrent Stroke (J-STARS).
Nagai Y; Kohriyama T; Origasa H; Minematsu K; Yokota C; Uchiyama S; Ibayashi S; Terayama Y; Takagi M; Kitagawa K; Nomura E; Hosomi N; Ohtsuki T; Yamawaki T; Matsubara Y; Nakamura M; Yamasaki Y; Mori E; Fukushima M; Kobayashi S; Shinohara Y; Yamaguchi T; Matsumoto M;
Int J Stroke; 2014 Feb; 9(2):232-9. PubMed ID: 24015915
[TBL] [Abstract][Full Text] [Related]
8. Non-high-density lipoprotein cholesterol and the development of coronary heart disease and stroke subtypes in a general Japanese population: the Hisayama Study.
Imamura T; Doi Y; Ninomiya T; Hata J; Nagata M; Ikeda F; Mukai N; Hirakawa Y; Yoshida D; Fukuhara M; Kitazono T; Kiyohara Y
Atherosclerosis; 2014 Apr; 233(2):343-348. PubMed ID: 24530960
[TBL] [Abstract][Full Text] [Related]
9. The Japan Statin Treatment Against Recurrent Stroke (J-STARS): A Multicenter, Randomized, Open-label, Parallel-group Study.
Hosomi N; Nagai Y; Kohriyama T; Ohtsuki T; Aoki S; Nezu T; Maruyama H; Sunami N; Yokota C; Kitagawa K; Terayama Y; Takagi M; Ibayashi S; Nakamura M; Origasa H; Fukushima M; Mori E; Minematsu K; Uchiyama S; Shinohara Y; Yamaguchi T; Matsumoto M;
EBioMedicine; 2015 Sep; 2(9):1071-8. PubMed ID: 26501105
[TBL] [Abstract][Full Text] [Related]
10. Elevated Serum Non-HDL (High-Density Lipoprotein) Cholesterol and Triglyceride Levels as Residual Risks for Myocardial Infarction Recurrence Under Statin Treatment.
Suzuki K; Oikawa T; Nochioka K; Miura M; Kasahara S; Sato M; Aoyanagi H; Shiroto T; Takahashi J; Miyata S; Sakata Y; Shimokawa H
Arterioscler Thromb Vasc Biol; 2019 May; 39(5):934-944. PubMed ID: 30866657
[TBL] [Abstract][Full Text] [Related]
11. On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study).
Khera AV; Wolfe ML; Cannon CP; Qin J; Rader DJ
Am J Cardiol; 2010 Aug; 106(4):451-6. PubMed ID: 20691300
[TBL] [Abstract][Full Text] [Related]
12. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Callahan A; Amarenco P; Goldstein LB; Sillesen H; Messig M; Samsa GP; Altafullah I; Ledbetter LY; MacLeod MJ; Scott R; Hennerici M; Zivin JA; Welch KM;
Arch Neurol; 2011 Oct; 68(10):1245-51. PubMed ID: 21670382
[TBL] [Abstract][Full Text] [Related]
13. Benefit of Targeting a LDL (Low-Density Lipoprotein) Cholesterol <70 mg/dL During 5 Years After Ischemic Stroke.
Amarenco P; Kim JS; Labreuche J; Charles H; Giroud M; Lee BC; Mahagne MH; Nighoghossian N; Gabriel Steg P; Vicaut É; Bruckert E;
Stroke; 2020 Apr; 51(4):1231-1239. PubMed ID: 32078484
[TBL] [Abstract][Full Text] [Related]
14. Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization. Perspectives from the CREDO-Kyoto registry cohort-2.
Natsuaki M; Furukawa Y; Morimoto T; Nakagawa Y; Ono K; Kaburagi S; Inada T; Mitsuoka H; Taniguchi R; Nakano A; Kita T; Sakata R; Kimura T;
Circ J; 2012; 76(6):1369-79. PubMed ID: 22447012
[TBL] [Abstract][Full Text] [Related]
15. Reduction in High-Sensitivity C-Reactive Protein Levels in Patients with Ischemic Stroke by Statin Treatment: Hs-CRP Sub-Study in J-STARS.
Kitagawa K; Hosomi N; Nagai Y; Kagimura T; Ohtsuki T; Origasa H; Minematsu K; Uchiyama S; Nakamura M; Matsumoto M;
J Atheroscler Thromb; 2017 Oct; 24(10):1039-1047. PubMed ID: 28302952
[TBL] [Abstract][Full Text] [Related]
16. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Amarenco P; Goldstein LB; Callahan A; Sillesen H; Hennerici MG; O'Neill BJ; Rudolph AE; Simunovic L; Zivin JA; Welch KM;
Atherosclerosis; 2009 Jun; 204(2):515-20. PubMed ID: 18962621
[TBL] [Abstract][Full Text] [Related]
17. Oxidized Low-Density Lipoprotein to High-Density Lipoprotein Ratio Predicts Recurrent Stroke in Minor Stroke or Transient Ischemic Attack.
Wang A; Li S; Zhang N; Dai L; Zuo Y; Wang Y; Meng X; Wang Y
Stroke; 2018 Nov; 49(11):2637-2642. PubMed ID: 30355199
[TBL] [Abstract][Full Text] [Related]
18. Yield of Dual Therapy With Statin and Ezetimibe in the Treat Stroke to Target Trial.
Amarenco P; Kim JS; Labreuche J; Charles H; Giroud M; Lee BC; Lavallée PC; Mahagne MH; Meseguer E; Nighoghossian N; Steg PG; Vicaut É; Bruckert E;
Stroke; 2022 Nov; 53(11):3260-3267. PubMed ID: 36154103
[TBL] [Abstract][Full Text] [Related]
19. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
Tani S; Nagao K; Hirayama A
Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
[TBL] [Abstract][Full Text] [Related]
20. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators.
Plehn JF; Davis BR; Sacks FM; Rouleau JL; Pfeffer MA; Bernstein V; Cuddy TE; Moyé LA; Piller LB; Rutherford J; Simpson LM; Braunwald E
Circulation; 1999 Jan; 99(2):216-23. PubMed ID: 9892586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
